Mesenchymal Precursor Cells as Adjunctive Therapy in Recipients of Contemporary Left Ventricular Assist Devices
Author(s) -
Deborah D. Ascheim,
Annetine C. Gelijns,
Daniel J. Goldstein,
Lemuel A. Moyé,
Nicholas G. Smedira,
Sangjin Lee,
C.T. Klodell,
Anita Szady,
Michael K. Parides,
Neal Jeffries,
Donna Skerrett,
Doris A. Taylor,
J. Eduardo Rame,
Carmelo A. Milano,
Joseph G. Rogers,
Janine Lynch,
Todd Dewey,
Eric J. Eichhorn,
Benjamin Sun,
David S. Feldman,
Robert D. Simari,
Patrick T. O’Gara,
Wendy C. TaddeiPeters,
Marissa A. Miller,
Yoshifumi Naka,
Emilia Bagiella,
Eric A. Rose,
Y. Joseph Woo
Publication year - 2014
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.113.007412
Subject(s) - medicine , ventricular assist device , ejection fraction , clinical endpoint , destination therapy , randomization , weaning , transplantation , cardiology , myocarditis , heart failure , surgery , randomized controlled trial
Allogeneic mesenchymal precursor cells (MPCs) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom